Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

f unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the sufficiency of Nile's available capital, timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are descr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... steps for its Oral Amphotericin B program.  The ... in vitro work involving samples from HIV/AIDS ... to complete pre clinical studies and regulatory filings ... clinical trial, utilizing approximately $700,000 of funding and ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... SCOTTSDALE, Ariz., Sept. 17 MedTrust Online, a ... options for challenging patient cancer cases, has surpassed 5,000 ... Online also announced today that world-renowned oncologist Dr. Henry ... advisors. , , "5,000 users is ...
... ... children successfully take antiviral medications to fight the H1N1 and seasonal flu viruses. By ... medicine as prescribed. , ... MD, (PRWEB) September 17, 2009 -- As new cases of the H1N1 virus (swine flu) ...
... YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain, ... Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... today reported that nimotuzumab has been approved for marketing ...
Cached Biology Technology:MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 3FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 4YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 4
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... planet,s leading questions is how to produce enough food ... The Food and Agriculture Organization of the United Nations ... next 40 years to feed a growing global population, ... rise in food production. Plants—grains, cereals, fruits, vegetables, ... Current research must tap into our knowledge of ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... Do you want that in a pill or a shot? ... choice. The problem with administering many medications orally is that ... site in the gastrointestinal tract where the medicine can be ... by Brown University researchers could solve the problem by safely ...
... with common blood pressure medications may cause hypotension ... older patients, requiring hospitalization, according to a study ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf ... are among the most widely prescribed antibiotics, with ...
... Stanford University School of Medicine, in collaboration with BioParadox, ... plasma as a promising biologic treatment for myocardial infarction ... online in Cardiovascular Revascularization Medicine and will ... Therapy for Cardiovascular Disease at Columbia University Medical Center, ...
Cached Biology News:Magnetically controlled pill could boost body's absorption of drugs 2RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks 2
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: